Novavax hunts for Australian manufacturer as CSL homes in on AstraZeneca vaccine production

Once a likely contender to produce Novavax's late-stage COVID-19 vaccine in Australia, local biotech CSL now says it'll be too busy manufacturing AstraZeneca's shot. CSL lacks the capacity to make both AstraZeneca and Novavax’s vaccines at the same time, a company spokeswoman told Fierce Pharma via email. The company is under contract to produce 50 million AZ doses for Australia and, at the government’s behest, will “remain fully focused on the production of the AstraZeneca vaccine,” she said. The company had previously suggested it might be able to chip in on Novavax's production, too.